Evidence map›Paper›PMID 34189636›Full record

ArticleInternational journal of clinical oncology2021

A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer.

Shunji Takahashi, Munetaka Takekuma, Kenji Tamura, Kazuhiro Takehara, Hiroyuki Nomura, Makiko Ono, Mayu Yunokawa, Daisuke Aoki

Open access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Nanoparticle-Based Combination Therapy for Ovarian Cancer.International journal of nanomedicine · 2023
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Shunji TakahashiCancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-0063, Japan.
Munetaka TakekumaShizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Kenji TamuraNational Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Kazuhiro TakeharaNational Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemotomachi, Matsuyama-shi, Ehime, 791-0245, Japan.
Hiroyuki NomuraKeio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Makiko OnoCancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-0063, Japan.
Mayu YunokawaCancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-0063, Japan.
Daisuke AokiKeio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. aoki@z7.keio.jp.ORCID http://orcid.org/0000-0002-9596-8326
Japanese Foundation For Cancer Research · JPFujita Health University · JPKeio University · JPShikoku Cancer Center · JPShimane University Hospital · JPShizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvanced relapsed ovarian cancer has a poor prognosis, and treatment options are limited.

methodsThis phase I trial investigated the dosage, safety, pharmacokinetics and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in Japanese patients with advanced relapsed ovarian, fallopian tube, or primary peritoneal cancer. Patients received trabectedin 0.9 or 1.1 mg/m

resultsEighteen patients were included. The MTD of trabectedin was determined as 1.1 mg/m

conclusionsTrabectedin, in combination with PLD, may have clinical benefits in Japanese patients with relapsed advanced ovarian cancer. The recommended dosage of trabectedin for further study in this population is 1.1 mg/m CLINICAL TRIAL REGISTRATION NUMBER: JapicCTI-163164.

Indexed as

Ovarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsDoxorubicinFemaleHumansNeoplasm Recurrence, LocalPolyethylene GlycolsTrabectedinDoxorubicinliposomal doxorubicinPolyethylene GlycolsTrabectedinJapanLiposomal doxorubicinOvarian cancerPhase IRecurrenceTrabectedin

Identifiers

PMID34189636
PMCPMC8449774
OpenAlexW3176787016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.